Shots:

• The US FDA has granted EUA for cobas SARS-CoV-2 & Influenza A/B Test for use on the cobas 6800/8800 Systems to qualitatively detects and differentiate SARS-CoV-2- Influenza A and B in patients suspected of having respiratory viral infection consistent with COVID-19
• The test is a multiplex RT-PCR assay intended to detect the virus in nasal/nasopharyngeal swab samples collected from the suspected individuals and is not intended for the detection of Influenza C virus
• The test is available in markets accepting the CE mark. The COVID-19 and influenza infection can hardly be differentiated based on symptoms- HCPs can confidently provide the right diagnosis and best course of treatment for patients

­ Ref: Roche | Image: Roche